US23285D1090
US23285D1090
Cytek Biosciences, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 705.81M EUR | 575.82M EUR | 564.35M EUR | 649.18M EUR |
Enterprise Value | 461.17M EUR | 528.44M EUR | 526.17M EUR | 582.07M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 77.57x | -- | -- | -- |
Price to Sales | 3.41x | 2.79x | 2.76x | 4.06x |
Price to Book | 2.19x | 1.79x | 1.72x | 1.9x |
EV/Revenue | 2.23x | 2.56x | 2.58x | 3.64x |
EV/EBITDA | -11.6x | -- | -- | -- |
Price to FCF (P/FCF) | 75.93x | -- | -- | -- |
EV/FCF | 49.61x | -- | -- | -- |
FCF Yield | 1.32% | -2.11% | -2.27% | -1.22% |